JP2006524190A - 薬剤のメントール溶液 - Google Patents

薬剤のメントール溶液 Download PDF

Info

Publication number
JP2006524190A
JP2006524190A JP2006501172A JP2006501172A JP2006524190A JP 2006524190 A JP2006524190 A JP 2006524190A JP 2006501172 A JP2006501172 A JP 2006501172A JP 2006501172 A JP2006501172 A JP 2006501172A JP 2006524190 A JP2006524190 A JP 2006524190A
Authority
JP
Japan
Prior art keywords
drug
drugs
menthol
bioavailability
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006501172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006524190A5 (enExample
Inventor
フラッシュナー−バラク,モシェ
イー. ラーナー,イザック
ローゼンバーガー,ベレド
モルダブスキ,ナオミ
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2006524190A publication Critical patent/JP2006524190A/ja
Publication of JP2006524190A5 publication Critical patent/JP2006524190A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006501172A 2003-02-20 2004-02-17 薬剤のメントール溶液 Pending JP2006524190A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44924603P 2003-02-20 2003-02-20
PCT/US2004/004684 WO2004073686A2 (en) 2003-02-20 2004-02-17 Menthol solutions of drugs

Publications (2)

Publication Number Publication Date
JP2006524190A true JP2006524190A (ja) 2006-10-26
JP2006524190A5 JP2006524190A5 (enExample) 2009-12-10

Family

ID=32908699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006501172A Pending JP2006524190A (ja) 2003-02-20 2004-02-17 薬剤のメントール溶液

Country Status (10)

Country Link
US (1) US20040198646A1 (enExample)
EP (1) EP1596832A2 (enExample)
JP (1) JP2006524190A (enExample)
KR (1) KR20050116368A (enExample)
CN (1) CN1882313A (enExample)
AU (1) AU2004212989A1 (enExample)
CA (1) CA2516798A1 (enExample)
EA (1) EA200501301A1 (enExample)
MX (1) MXPA05008902A (enExample)
WO (1) WO2004073686A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508249A (ja) * 2003-10-10 2007-04-05 ライフサイクル ファーマ アクティーゼルスカブ フィブラートとスタチンを含む固体剤型
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
JP5069001B2 (ja) 2003-10-10 2012-11-07 ベロクシス ファーマシューティカルズ エー/エス フィブラートを含む固体投与形態
US20070166360A1 (en) * 2004-03-31 2007-07-19 Kowa Co., Ltd. External preparation
EP1720523A2 (en) * 2004-08-13 2006-11-15 Teva Pharmaceutical Industries Ltd Cyclosporin formulations
EA200701750A1 (ru) * 2005-03-30 2008-02-28 Тева Фармасьютикал Индастриес Лтд. Улучшенные составы фенофибрата, содержащие ментол или пэг/полоксамер
EP1707197A1 (en) 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and a surfactant mixture
JP2008534586A (ja) * 2005-03-30 2008-08-28 テバ ファーマシューティカル インダストリーズ リミティド フェノフィブレートの改良された製剤
EP1898922A4 (en) * 2005-07-04 2012-03-14 Ramu Krishnan MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
US20240041974A1 (en) * 2019-09-09 2024-02-08 Taejoon Pharmaceutical Co., Ltd. Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11507356A (ja) * 1995-06-07 1999-06-29 アブマックス,インコーポレイティド 経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331318B1 (en) * 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
ATE288255T1 (de) * 1996-04-12 2005-02-15 Novadel Pharma Inc Polares bukkales spray
US20010049363A1 (en) * 1998-05-08 2001-12-06 Warner-Lambert Company Oral composition containing NSAIDs and essential oils
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
KR20040098023A (ko) * 2002-03-26 2004-11-18 테바 파마슈티컬 인더스트리즈 리미티드 약물 미세입자

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11507356A (ja) * 1995-06-07 1999-06-29 アブマックス,インコーポレイティド 経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6009031595, 医療薬日本医薬品集, 19991025, p. 1422 *

Also Published As

Publication number Publication date
CA2516798A1 (en) 2004-09-02
CN1882313A (zh) 2006-12-20
KR20050116368A (ko) 2005-12-12
WO2004073686A3 (en) 2004-11-04
MXPA05008902A (es) 2005-10-05
US20040198646A1 (en) 2004-10-07
AU2004212989A1 (en) 2004-09-02
EA200501301A1 (ru) 2006-04-28
EP1596832A2 (en) 2005-11-23
WO2004073686A2 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
CA2762013C (en) Granulation of pirfenidone and pharmaceutically acceptable excipients
BRPI0212922B1 (pt) Composição farmacêutica na forma de um comprimido dispersável compreendendo uma dispersão sólida de 40-o-(2-hidroxietil)-rapamicina, seu processo de preparação e uso da dita composição
JP2006524190A (ja) 薬剤のメントール溶液
JPH10259131A (ja) 経口投与用ラパマイシン処方
TW201521786A (zh) 胺碘酮類似物(budiodarone)調配物
JP2006524190A5 (enExample)
KR20090086686A (ko) 용출율이 개선된 실리마린 함유 약학적 조성물 및 이의제조방법
US20060141028A1 (en) Cyclosporin formulations
US20130143848A1 (en) Use of megestrol acetate for improving heart function and the treatment of heart insufficiency
EP1465607B1 (fr) Compositions pharmaceutiques a liberation modifiee
CN109496152A (zh) 癸氧喹酯组合物的肌肉内库存及其预防和治疗的方法
JP7432501B2 (ja) チモキノン含有組成物の調製法
US20080161404A1 (en) Bicalutamide for Delivering Increasing Steady State Plasma Levels
AU2008200464A1 (en) Menthol solutions of drugs
JP2688266B2 (ja) アルドース還元酵素阻害作用を有し且つ吸収性の良好な薬剤組成物
AU2013201986A1 (en) Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients
AU2014240300C1 (en) Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients
CN103142596A (zh) 一种含替米沙坦和匹伐他汀的药物组合物
HK1168758A (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
HK1117762B (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090929

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091006

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20091023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100928